Science Corporation, a California-based biotechnology firm specializing in brain-computer interface (BCI) technology, has announced a significant milestone in its mission to restore vision to the blind. Following the successful completion of a clinical trial for its Prima retinal implant, the company has raised approximately $490 million in total funding since its inception in 2021. This capital injection, led by a consortium of high-profile venture capital firms including Khosla Ventures, Lightspeed Venture Partners, Y Combinator, and IQT, positions the company as a frontrunner in the competitive BCI landscape. The company has now formally submitted applications for regulatory approval in both the European Union and the United States, seeking to bring its vision-restoration technology to a global market of millions suffering from degenerative eye diseases.
The announcement comes on the heels of peer-reviewed data published in the New England Journal of Medicine, which detailed the outcomes of a clinical trial involving patients with advanced geographic atrophy (GA), the late-stage form of dry age-related macular degeneration (AMD). The study demonstrated that the Prima system, a subretinal implant paired with specialized computer-augmented glasses, could effectively function as a bridge for damaged neural pathways, allowing patients who had lost their central vision to regain the ability to read and recognize shapes.
Technical Foundations of the Prima System
The Prima system represents a departure from traditional neural interface designs. While many BCI companies focus on direct cortical implants—placing electrodes on the surface of the brain—Science Corporation’s Prima device targets the retina. The system is designed specifically for patients whose photoreceptors (the light-sensing cells of the eye) have degraded, but whose underlying neural architecture, including the optic nerve, remains intact.
The hardware consists of three primary components: a 2-millimeter-square photovoltaic implant, a pair of high-tech glasses equipped with a miniature camera, and an external processor. The implant, which is surgically placed beneath the retina, contains 378 independent pixels. These pixels do not require internal wires or batteries; instead, they are powered by infrared light projected from the glasses.
The process begins when the camera on the glasses captures the visual environment. A built-in computer processes these images and translates them into patterns of infrared light. This light is then projected through the pupil onto the subretinal chip. The chip’s photovoltaic pixels convert the infrared energy into electrical pulses, which stimulate the remaining functional retinal cells. These cells then transmit the signal through the optic nerve to the brain’s visual cortex, where it is interpreted as sight. This "artificial vision" is designed to integrate with the patient’s remaining peripheral vision, providing a more comprehensive visual experience than previous technologies.
Clinical Trial Data and Patient Outcomes
The pivotal clinical trial, conducted across several sites in Europe, provided the empirical foundation for the company’s regulatory filings. The study initially enrolled 38 participants, all of whom suffered from profound vision loss due to advanced dry AMD. These patients had reached a stage of the disease where their central vision was entirely obscured by "scotomas" or blind spots, making tasks such as reading, driving, or recognizing faces impossible.
Of the 38 participants, 32 were followed through the full 12-month primary endpoint. The results were described by the company as transformative. Twenty-six of the assessed patients achieved a clinically meaningful improvement in visual acuity. Specifically, patients who were previously unable to see letters on a standard eye chart were able to read not just individual letters, but full words and numbers. Some participants reported the ability to read books and identify facial features of family members—milestones that had been considered unreachable for those with late-stage GA.
The data indicated that the system was well-tolerated, with no significant safety concerns reported regarding the surgical implantation process or the long-term presence of the chip in the subretinal space. This safety profile is a critical component of the company’s submission for the CE mark in Europe and its application to the U.S. Food and Drug Administration (FDA).
Contextual Background: The Global Burden of Macular Degeneration
The development of the Prima device addresses one of the most significant unmet needs in modern ophthalmology. Age-related macular degeneration is a leading cause of vision loss worldwide, particularly in developed nations with aging populations. It is estimated that nearly 200 million people globally are affected by some form of AMD, with that number expected to rise as life expectancy increases.
While "wet" AMD—characterized by the growth of abnormal blood vessels—can often be managed with periodic injections of anti-VEGF medications, the "dry" form of the disease has historically been much harder to treat. Geographic atrophy represents the most severe manifestation of dry AMD, involving the progressive death of retinal pigment epithelium and photoreceptors. Until very recently, there were no FDA-approved treatments for GA. While new drugs like pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) have been approved to slow the progression of the disease, they cannot restore vision that has already been lost. Science Corporation’s technology is aimed specifically at this "lost" population, offering a functional recovery rather than a mere slowing of decline.
The Evolution of Science Corporation and the BCI Market
Science Corporation was founded by Max Hodak, who previously served as the president of Neuralink, the BCI company co-founded by Elon Musk. Hodak’s departure from Neuralink and subsequent founding of Science Corporation marked a strategic shift in the industry toward more specialized, disease-specific applications of neural interfaces.
The company’s trajectory changed significantly in early 2024 when it acquired the IP and assets of Pixium Vision, a French medtech firm that had originally developed the Prima technology. The acquisition allowed Science Corporation to integrate Pixium’s advanced retinal work with its own proprietary "Science Eye" platform. This synergy has accelerated the timeline for commercialization, moving the company from the research and development phase into the regulatory and clinical execution phase.
The BCI market is currently experiencing a period of intense growth and investment. Companies like Synchron, which uses a stent-like device to access the brain through blood vessels, and Blackrock Neurotech, which uses high-density microelectrode arrays, are also racing toward commercialization. However, Science Corporation’s focus on the retina provides a distinct advantage: the surgical procedure is less invasive than open-brain surgery, and the target demographic is significantly larger than the population of patients with total paralysis who are the primary focus of other BCI firms.
Strategic Objectives and Economic Implications
With $490 million in capital, Science Corporation is shifting its focus toward scaling its manufacturing and clinical operations. Darius Shahida, the company’s Chief Strategy Officer, emphasized that the goal is not just technological innovation, but the creation of a sustainable, profitable business model. "Our imperative is to become the first BCI company to scale and achieve profitability," Shahida stated.
Achieving profitability in the medtech sector requires navigating complex reimbursement landscapes. For the Prima system to be successful, Science Corporation will need to secure coverage from private insurers and government programs like Medicare. This will depend on proving not only the clinical efficacy of the device but also its cost-effectiveness in reducing the long-term economic burden of blindness, which includes the cost of home care, lost productivity, and increased risk of falls and other injuries among the elderly.
The company’s roadmap includes expanding clinical trials to other retinal pathologies. Preliminary work is already underway to test the system in patients with Stargardt disease—a genetic form of macular degeneration that affects younger people—and retinitis pigmentosa, a group of rare genetic disorders that involve a breakdown and loss of cells in the retina.
Timeline of Recent Developments
The journey to the current funding and regulatory status has been marked by several key milestones:
- 2021: Science Corporation is founded by Max Hodak, securing initial seed and Series A funding.
- 2022-2023: Development of the "Science Eye" platform, a separate optogenetic approach to vision restoration.
- Early 2024: Science Corporation acquires Pixium Vision, bringing the Prima retinal implant into its portfolio.
- Late 2024: Publication of the PRIMAvera clinical trial results in the New England Journal of Medicine, showing significant visual acuity gains in 38 patients.
- Late 2024: Formal submission for CE mark in Europe and engagement with the FDA for U.S. approval.
- Current Status: Closing of the $490 million funding round and preparation for commercial launch pending regulatory clearance.
Broader Impact and Industry Analysis
The success of Science Corporation reflects a broader trend in the "neurotech" sector: the move toward sensory restoration. While early BCI work was often focused on "output" (allowing a paralyzed person to move a cursor or robotic arm), Science Corporation is proving the viability of "input" BCIs, which feed information back into the nervous system.
If approved, the Prima system would represent the first successful commercialization of a subretinal BCI. Previous attempts, such as the Argus II by Second Sight, faced challenges due to the complexity of the hardware and limited resolution. By utilizing photovoltaic technology and an external infrared projector, Science Corporation has simplified the internal hardware, potentially increasing the longevity and reliability of the implant.
Industry analysts suggest that the success of Science Corporation could trigger a wave of mergers and acquisitions in the ophthalmology and neurology sectors. Traditional eye-care giants, which have focused primarily on pharmaceuticals and cataract lenses, may look to BCI technology as the next frontier for treating incurable blindness.
As Science Corporation awaits the decision of European and American regulators, the medical community remains cautiously optimistic. If the Prima device achieves widespread adoption, it could fundamentally change the prognosis for millions of people diagnosed with age-related macular degeneration, transforming a diagnosis of "untreatable blindness" into a manageable condition through the marriage of biology and advanced computing. For now, the $490 million investment serves as a powerful vote of confidence in a future where neural interfaces are a standard part of medical care.